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Abstract
To examine the effect on serum lipase activity and protein concentration of
intravenous infusions of glucagon-like peptide-1 (GLP-1) and peptide YY
(PYY3-36) and of an ad libitum meal in healthy overweight men. Twenty-five
healthy, male subjects participated in this randomized, double-blinded, pla-
cebo-controlled 4-arm crossover study (Body Mass Index (BMI): 29  3 kg/
m2, age: 33  9 years). On separate days, the subjects received a 150-min
intravenous infusion of either (1) 0.8 pmol/kg/min PYY3-36, (2) 1.0 pmol/kg/
min GLP-1, (3) 1 + 2, or (4) placebo. Samples were collected throughout the
infusion and after intake of an ad libitum meal for measurement of serum
lipase. Serum lipase levels measured by enzyme-linked immunosorbent assay
(ELISA) following mono-infusions of GLP-1 and PYY3-36 were comparable to
serum lipase levels following placebo (P = 0.054 and P = 0.873, respectively).
Following the co-infusion of GLP-1 and PYY3-36, serum lipase levels measured
by ELISA decreased over time compared to placebo (P = 0.012). However, the
between-group difference was not consistent when each time point was ana-
lyzed separately. On the placebo day, serum lipase levels measured by ELISA
after an ad libitum meal rose slightly compared to the preprandial values
(P = 0.003). There was strong correlation between serum lipase levels mea-
sured by ELISA and LIPC Lipase colorimetric assay (COBAS) (0.94 < r;
<0.0001). Infusions of GLP-1 and PYY3-36, separately or in combination, did
not increase serum lipase. However, a small increase in serum lipase may
occur in response to a meal.
Introduction
Changes in the secretion of the gastro-intestinal hor-
mones, glucagon-like peptide-1 (GLP-1) and peptide YY
(PYY), are believed to play an important role for weight
loss after Roux-en-Y gastric bypass (RYGB) (le Roux
et al. 2007; Jacobsen et al. 2012). In addition to its role as
an important regulator of appetite, GLP-1 is also involved
in the postoperative remission of type 2 diabetes mellitus
(T2D) (le Roux et al. 2007; Jorgensen et al. 2013).
Agonists of the GLP-1 receptor (GLP-1R), including
exenatide (Byetta) and liraglutide (Victoza) have been
approved for the treatment of T2D and these drugs effec-
tively reduce blood glucose, body weight, and systolic
blood pressure. The mechanism by which GLP-1R ago-
nists reduce blood glucose involves potentiation of
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
the American Physiological Society and The Physiological Society.
This is an open access article under the terms of the Creative Commons Attribution License,
which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
2016 | Vol. 4 | Iss. 18 | e12980
Page 1
Physiological Reports ISSN 2051-817X
glucose-induced insulin secretion from the pancreatic b-
cells (Hare et al. 2009). It has also been shown that the
production of glucose from the liver is reduced during
treatment with liraglutide via an inhibitory effect on glu-
cagon secretion (Hare et al. 2009). Thus, the effect of
GLP-1R agonists on the endocrine part of the pancreas is
well documented, however, whether there is any effect of
these agonists on the exocrine part of the pancreas is not
clear. There are data indicating that GLP-1Rs are only
present on the pancreatic b-cells, while other data indi-
cate that the acinar cells of the exocrine pancreas also
contain GLP-1Rs at a lower density (Pyke et al. 2014;
Waser et al. 2015).
The enzyme pancreatic lipase is released from the aci-
nar cells of the exocrine part of the pancreas to the duo-
denum during a meal and acts to hydrolyze triglycerides.
In the clinic, this enzyme is used as a marker of pancre-
atic damage. An increase in serum pancreatic lipase at
approximately 10–12 U/L has been reported after 2–
4 weeks of treatment in clinical studies with several GLP-
1R agonists (Bastyr et al. 2009; Steinberg et al. 2012).
Although this increase is within the normal range (13–
60 U/L) (DeVries et al. 2012), the mechanism needs fur-
ther investigation.
Whether the release of lipase to the gut during a meal
is also accompanied by an increase in serum lipase, as a
part of a normal postprandial response, is unclear. Thus,
it would be of interest to measure serum lipase in the
pre- and postprandial phases of a meal. Acute changes in
the levels of serum lipase in patients who are treated with
native GLP-1 or PYY3-36 have not been reported either,
and such a study would be relevant in order to elucidate
whether these peptides have an immediate and direct
effect on the exocrine part of the pancreas.
Previously, we investigated the effect of intravenous
infusion of GLP-1 and PYY3-36, separately and in combi-
nation, on energy intake, energy expenditure, and appetite
sensations in healthy overweight men (Schmidt et al.
2014). In this post hoc substudy, we included additional
analyses to elucidate whether infusion of GLP-1 and
PYY3-36 as well as an ad libitum meal increased serum
lipase. Furthermore, we compared the standard assay used
in most clinical trials for assessment of lipase activity, the
LIPC Lipase colorimetric assay (COBAS) with a dedicated
enzyme-linked immunosorbent assay (ELISA) assay for
the human lipase protein.
Methods
Study population
Subjects included 25 moderately overweight (BMI ≥ 25),
healthy Caucasian men, aged 18–50 years (Schmidt et al.
2014). The study was approved by the Municipal Ethical
Committee of Copenhagen/Scientific Ethics Committee of
the Capital Regions of Denmark (journal no. H-1-2009-
083 and H-3-2013-091) and carried out in accordance
with the Helsinki-II Declaration/Declaration of Helsinki
and by the Danish Data Protection Agency (journal no.
2007-54-0296). The study followed the guidelines of Good
Clinical Practice (GCP) and was registered at Clinical Tri-
als (ID# NCT00940134).
Study design
As described previously (Schmidt et al. 2014), the study
was a randomized, double-blinded, 4-arm crossover
design. Subjects attended the Department of Nutrition,
Exercise and Sports on four separate test days and
received a 150-min intravenous infusion of either (1)
GLP-1, (2) PYY3-36, (3) GLP-1 + PYY3-36, or (4) placebo.
Doses of 0.5 pmol/kg/min of GLP-17-36 amide and
0.4 pmol/kg/min of PYY3-36 for the first 45 min, and
1.0 pmol/kg/min GLP-17-36 amide and 0.8 pmol/kg/min
of PYY3-36 for the remaining 105 min were chosen
(Fig. 1). Synthetic GLP-17-36 amide and PYY3-36 from
polypeptides (Wolfenb€uttel, Germany) with a purity of
>97% were used. Purity and structure were estimated by
high-performance liquid chromatography (HPLC) analy-
sis, mass spectrometry, and sequence analysis. PYY3-36
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Figure 1. Overview of a test day. Infusion of GLP-1, PYY3-36, GLP-1 + PYY3-36, or placebo was initiated at time 0 and continued for 150 min
while the ad libitum meal was served at time 120. GLP-1, glucagon-like peptide-1; PYY, peptide YY.
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and GLP-17-36 amide alone or in combination, were dis-
solved in saline with 2% human albumin in order to limit
adhesion to infusion material and the solutions were dis-
tributed in glass tubes. The solutions and placebo (saline
and albumin only) were prepared according to Good
Manufacturing Practice (GMP) and tested for sterility
and pyrogenic content at the Capital Region Pharmacy,
Herlev. Treatments were given in a random order, and
both the subjects and the researchers involved with the
subjects were blinded to the treatments.
On each test day (Visit 1–4) (Fig. 1), the subject
arrived at 7:30 AM after an overnight fast. To limit fluctu-
ations in glycogen stores and energy balance, subjects
received a standardized dinner, and were instructed to
refrain from alcohol and strenuous physical activities on
the day prior to the test days. Intravenous catheters were
inserted into an antecubital vein in each arm; one for
hormone infusion and another for sampling of blood.
Infusions began at time 0 and were continued for a total
of 150 min. Blood samples were collected every 30 min
and the same measurements as those collected at baseline
were repeated. After 120 min, an ad libitum meal was
served. Thirty minutes after initiation of the meal
(150 min after start of infusion), the last blood samples
were drawn before the infusion was stopped.
Biochemical measures
ELISA for determination of total lipase
concentration
This sandwich ELISA was originally developed by Grand-
val et al. (2004). In brief, analyses were performed in 96-
well polyvinyl chloride (PVC) microtiter plates (Max-
isorp, Nunc). Plates were coated at 4°C overnight with a
purified rabbit anti-human pancreatic lipase polyclonal
antibody used as a catcher antibody. Plates were washed
and the standards of human pancreatic lipase were pre-
pared at concentrations ranging from 0 to 1–5 lg/L as
well as unknown plasma samples were added to the
plates. Incubation proceeded at 37°C for 1 h. After a
washing step, a biotinylated monoclonal antibody specific
for human pancreatic lipase was added to the plates, fol-
lowed by one hour incubation at 4°C. A solution of
ExtrAvidin peroxidase conjugate was added and the
plates were incubated at 37°C for 45 min. The plates
were washed three times and freshly prepared peroxidase
substrate solution was added to each well. The plates
were kept at room temperature in the dark for 15 min
and the enzyme reaction was stopped by the addition of
4 mol/L H2SO4 to each well. The optical density was
measured at 450–620 nm using a Tecan Sunrise spec-
trophotometer.
LIPC Lipase colorimetric assay
This method is based on the cleavage of a specific chro-
mogenic lipase substrate 1,2-O-dilauryl-rac-glycero-3-glu-
taric acid-(6-methylresorufin) ester emulsified with bile
acids. The pancreatic enzyme activity was determined
specifically by the combination of bile acid and colipase
used in this assay. Virtually, no lipase activity was
detected in the absence of colipase. Colipase only activates
pancreatic lipase, but not other lipolytic enzymes found
in serum. The high amount of cholates ensures that the
esterases present in the serum do not react with the chro-
mogenic substrate due to the highly negative surface
charge.
Statistical analysis
Linear mixed models were used for evaluating lipase levels
preprandially, one analysis per assay. These models
included time-treatment interactions as well as adjust-
ment for baseline body weight and carry-over as fixed
effects and subject-by-period random effects. Concentra-
tions were logarithm-transformed if needed. Differences
in trends over time between intervention groups were
evaluated using chi-square tests. Pairwise comparisons
between groups per time points were also made (using
model-based t-tests). Model checking was based on visual
inspection of residual and normal probability plots. Post-
prandially, concentrations were analyzed using analysis of
covariance with same adjustments as above. In addition,
we adjusted for meal size and concentration recorded
prior to the ad libitum meal; these analyses were carried
out both for all data (pooling groups) and for placebo
data only. Pairwise comparisons between groups were
considered. For comparison of the two serum lipase
assays, a Pearson correlation was made. Additionally,
correlation analyses were made to explore associations
between changes in serum lipase levels and meal size.
The statistical environment R was used for the analyses
(R Core Team, 2012). A significance level of 0.05 was
used.
Results
The effect of infusion of GLP-1, PYY3-36 and
GLP-1 + PYY3-36 on lipase levels in serum
In a model summarizing the trend for all preprandial
time points (30–120 min) and taking baseline differences
into account, serum lipase levels following mono-infu-
sions of GLP-1 and PYY3-36 were comparable to serum
lipase levels following placebo (P = 0.054 and P = 0.87,
respectively) (Figs. 2 and 3). Following co-infusion of
ª 2016 The Authors. Physiological Reports published by Wiley Periodicals, Inc. on behalf of
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GLP-1 and PYY3-36, serum lipase levels measured by
ELISA actually decreased over time compared to placebo
(P = 0.012) (Figs. 2 and 3). However, this between-group
difference was no longer present when each time point
was analyzed separately.
We performed similar analyses on serum lipase levels
measured by COBAS. In agreement with data from the
ELISA, we found no between-group differences when each
time point was analyzed separately and following adjust-
ments for multiple testing.
The effect of a meal on lipase levels in serum
On the placebo day, serum lipase levels measured by
ELISA after an ad libitum meal (at 150 min) were higher
Figure 2. Serum levels of lipase measured by ELISA following
infusion of GLP-1, PYY3-36, GLP-1 + PYY3-36, and placebo. GLP-1,
glucagon-like peptide-1; PYY, peptide YY.
Figure 3. Serum levels of lipase measured by ELISA for the individual subjects following infusion of (A) GLP-1, (B) PYY3-36, (C) GLP-1 + PYY3-
36, and (D) placebo GLP-1, glucagon-like peptide-1; PYY, peptide YY.
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than preprandial (at 120 min) (P = 0.003) (Figs. 2 and
3D). In a model adjusting for the preprandial measure-
ment, the postprandial levels were not different between
placebo and the active treatments groups (GLP-1:
P = 0.27, PYY: P = 0.41, co-infusion: P = 0.60) (Fig. 2).
We neither found association between change in serum
lipase (postprandial – preprandial) and energy intake dur-
ing the ad libitum meal in a pooled analysis (P = 0.16)
nor when looking at the placebo group separately
(P = 0.63). Analyses on serum lipase levels measured by
COBAS led to similar conclusions.
Correlation of lipase levels in serum
measured by a standard colorimetric assay
versus an immunological ELISA assay
Serum lipase activity was measured by COBAS at fasting,
at all preprandial time points, and after an ad libitum
meal and these data were compared with data obtained
from ELISA. The two methods were highly correlated
(0.94 < r < 0.98; P < 0.0001) (Fig. 4).
Discussion
Effects of the infusions
Our data do not support the initial hypothesis that infu-
sions of GLP-1 and PYY3-36, separately or in combination,
increase levels of lipase in serum. In contrast, the trends
over time analysis showed that, if anything, co-infusion
slightly lowered the lipase levels compared to placebo.
Similarly, a weak trend toward a decrease in levels of
lipase following GLP-1 infusion compared to placebo was
observed.
Evidently, the increase in serum lipase levels observed
after weeks of treatment with GLP-1R agonists in clinical
trials could not be confirmed in this “acute” setting and
with the levels of GLP-1 infusion applied in this study.
We chose the infusion dose levels based on an attempt to
elicit an effect on energy intake while avoiding unaccept-
able side effects in the form of nausea.
The results from other clinical studies indicate that the
serum lipase levels may be higher and more variable in
patients with T2D compared with nondiabetic obese
patients (DeVries et al. 2012). The reason for this is
unknown, but patients with T2D generally have an
increased risk of developing pancreatitis as well (Noel
et al. 2009). As only healthy subjects were included in this
study, we cannot exclude that serum lipase levels would
change differently following infusions of GLP-1 and
PYY3-36 in patients with T2D patients, and understanding
the mechanism behind the increase in serum lipase that
has been reported with Trulicity, Byetta, and Victoza
treatment, therefore, requires further studies conducted
on this specific population.
The effect of a meal
Serum lipase increased slightly following an ad libitum
meal on the placebo day. When analyzed together, there
was no significant difference in serum lipase between pla-
cebo and the different hormone infusions. The increased
release of lipase to the intestinal lumen during a meal
intake might be expected to be associated with a small
increase in plasma levels also, perhaps due to leakage from
the duct system or the acinar cells. Whether the effect of a
meal on serum lipase levels are modified by infusions of
GLP-1 and PYY3-36 cannot be settled by the present proto-
col due to differences in meal size resulting from the hor-
mone infusions. Although we found no association
between changes in serum lipase and energy intake in
pooled analyses, a link between these variables cannot be
ruled out entirely. Thus, it is possible that subjects with a
naturally high lipase response to a meal are also more sensi-
tive to a stimulatory effect of GLP-1 or PYY3-36 treatments.
Studies with sample size large enough for data to be strati-
fied according to meal responses are therefore warranted.
COBAS versus ELISA
Most clinical trials have used the COBAS assay for analy-
sis of serum lipase. This assay is relatively specific to pan-
creatic lipase activity due to the activation by colipase,
but the increased activity observed during chronic GLP-1
RA treatment might actually result from interference on
lipase activity by other circulating factors or from hitherto
uncharacterized lipolytic activity, rather than an increased
Figure 4. Correlation between levels of lipase in serum measured
by COBAS versus ELISA (0.94 < r < 0.98; P < 0.0001).
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release to the blood stream from the pancreas. Therefore,
we also analyzed all samples for the pancreatic lipase pro-
tein using a sandwich-type ELISA assay. Upon compar-
ison of the results obtained with the two methods, the
correlation between these methods was high, confirming
that a tight relationship exists between the plasma pancre-
atic lipase activity and the actual concentration of the
enzyme protein. Based on this comparison, it seems safe
to conclude that the activity measured by the COBAS
assay is an accurate measure of the presence and therefore
the leak/constitutive release of the enzyme from the pan-
creas.
Limitations
This study was primarily designed to investigate a potential
synergistic effect of GLP-1 and PYY3-36 on energy intake,
and the meal size was therefore not standardized, making
it difficult to differentiate between effects of the infusions
and effects of the meal when evaluating the postprandial
serum lipase levels. Our aim was to include overweight
subjects with the assumption that these subjects are at
higher risk of metabolic abnormalities and are more eligi-
ble for future treatment with a GLP-1 RA. However, the
use of a BMI ≥ 25 as a cut-off point for this purpose can
be criticized, and it is likely that our population consist of
a mix of metabolically healthy and unhealthy subjects, who
might have different baseline levels and respond differently
to exposure of GLP-1 and PYY3-36. As overweight is not
necessarily accompanied by metabolic abnormalities
adjusting for body weight, as we did in our analysis, does
not overcome this problem.
Conclusion
Our data do not support that acute infusions of GLP-1
and PYY3-36, separately or in combination, increase lipase
in serum. However, a small increase in serum lipase was
observed in response to an ad libitum meal. We found a
high correlation between the results of measurements of
pancreatic lipase activity and lipase protein in plasma,
indicating that the lipase activity is closely related to the
presence of the lipase protein.
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